Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion.
about
A Metabolic Immune Checkpoint: Adenosine in Tumor MicroenvironmentNT5E mutations that cause human disease are associated with intracellular mistrafficking of NT5E proteinPolyclonal rabbit anti-human ovarian cancer globulins inhibit tumor growth through apoptosis involving the caspase signaling.The roles of CD73 in cancerTargeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacyDiet- and Genetically-Induced Obesity Differentially Affect the Fecal Microbiome and Metabolome in Apc1638N MiceCD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.Ecto-5'-Nucleotidase (CD73) Deficiency in Mycobacterium tuberculosis-Infected Mice Enhances Neutrophil Recruitment1α,25-dihydroxyvitamin D3 acts via transforming growth factor-β to up-regulate expression of immunosuppressive CD73 on human CD4+ Foxp3- T cellsAnti-CD73 in cancer immunotherapy: awakening new opportunities.Sesamin protects against renal ischemia reperfusion injury by promoting CD39-adenosine-A2AR signal pathway in mice.MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma.The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.Monitoring Cell Proliferation by Dye Dilution: Considerations for Probe Selection.[Novel Immuno-oncology Therapy: Current Status of Clinical Research and Prospect of Application].Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?Exomechip Analyses Identify Genes Affecting Mortality after HLA-Matched Unrelated Donor Blood and Marrow Transplantation.CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells.Tumor-infiltrating CD39+γδTregs are novel immunosuppressive T cells in human colorectal cancer.Tumor immunotherapy: New aspects of natural killer cells.Targeting adenosine for cancer immunotherapy.
P2860
Q26749571-F4546D52-684E-43E5-A349-472B1302D5FAQ28539242-725CE3E3-6B13-4AF1-A4BF-788C36778204Q33612686-582980DB-CC0F-4EE7-BE9E-8FB39837A254Q34003164-51520D1F-C3D7-4AC1-A555-68AA242D301AQ34550649-CF40C347-BE09-4174-9A28-6BFB257128D6Q35748788-4CA3DF69-F926-4D32-929B-6F8C960C7810Q35941350-B5269C72-D160-406A-9586-BAFCD692CE73Q35947381-B85276BF-F741-450E-A10A-68F6E4862907Q36176421-70B3C760-3BD7-435A-B396-BADA22F3514DQ36709157-A6BF969D-138B-4B02-A149-C542E1C77056Q36964153-F6651B45-E66D-41AB-B508-384731A04249Q37536763-F72FACCA-9562-43E6-921D-0F266ECD35B4Q39397379-0C98770C-BB4E-4B1E-B1E0-972509B63BDAQ46026307-0138FC73-4CA5-4D1F-830D-4BBC0EC91C99Q47602012-21B416A9-10F4-4AC8-8E2E-B4048F3DEDEEQ49958882-C2F43301-F94C-4661-A9EB-0B8760FE0F02Q52323624-AD483623-A6F9-4167-ADA5-CFEBCCEFEA2EQ52611870-36D3751F-DECE-429B-98C6-5AE82A9E982AQ52649982-B00DDCDC-7039-49F5-9F95-54666BA020AEQ53399267-9070AEEE-7A23-47C3-AB3B-D8E8645A7D0BQ55107050-EED7DF59-5F89-4011-BF7A-B427F302C283Q55330380-AB778EFF-F8C7-4E45-99A9-0DD75FC8A76D
P2860
Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Anti-CD39 and anti-CD73 antibo ...... sine-dependent immune evasion.
@en
type
label
Anti-CD39 and anti-CD73 antibo ...... sine-dependent immune evasion.
@en
prefLabel
Anti-CD39 and anti-CD73 antibo ...... sine-dependent immune evasion.
@en
P2093
P2860
P1476
Anti-CD39 and anti-CD73 antibo ...... sine-dependent immune evasion.
@en
P2093
Arnd Hönig
Itsaso Montalbán Del Barrio
Jenny Strohschein
Joachim Diessner
Johannes Dietl
Roland G Stein
Sebastian Fm Häusler
P2860
P304
P407
P577
2014-01-15T00:00:00Z